Table 3.
Incidence of treatment-emergent adverse events occurring in > 2% of patients
| Preferred Term | 2-DG 63 mg + SOC N = 22 |
SOC1 N = 22 |
2-DG 90 mg + SOC N = 22 |
2-DG 126 mg + SOC N = 21 |
SOC2 N = 22 |
SOC (SOC1 + SOC2) N = 44 |
Total N = 109 |
|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Hyperglycaemia | 1 (4.5) | 2 (9.1) | 1 (4.5) | 2 (9.5) | 4 (18.2) | 6 (13.6) | 10 (9.2) |
| Palpitations | 2 (9.1) | 0 | 2 (9.1) | 0 | 0 | 0 | 4 (3.7) |
| Dizziness | 2 (9.1) | 0 | 2 (9.1) | 0 | 0 | 0 | 4 (3.7) |
| Diarrhea | 1 (4.5) | 0 | 2 (9.1) | 0 | 0 | 0 | 3 (2.8) |
| Hyperhidrosis | 2 (9.1) | 0 | 0 | 1 (4.8) | 0 | 0 | 3 (2.8) |
2-DG 2-deoxy-d-glucose, SOC standard of care, SOC1 SOC in Part A of the study, SOC2 SOC in Part B of the study
N: Total number of patients in the specified treatment group
n: Number of patients with the adverse events of the preferred term